Novartis AG ADR (NVS) News
Filter NVS News Items
NVS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NVS News Highlights
- NVS's 30 day story count now stands at 23.
- Over the past 21 days, the trend for NVS's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
- AMP, LI and DRUG are the most mentioned tickers in articles about NVS.
Latest NVS News From Around the Web
Below are the latest news stories about NOVARTIS AG that investors may wish to consider to help them evaluate NVS as an investment opportunity.
Novartis (NVS) Dips More Than Broader Markets: What You Should KnowNovartis (NVS) closed the most recent trading day at $101.86, moving -0.46% from the previous trading session. |
Novartis completes divestment of ‘front of eye’ ophthalmology assetsDivestment includes Xiidra®, on-market treatment for dry eye disease and additional ophthalmic investigational therapiesNovartis advances strategy of focused portfolio and prioritized therapeutic areas for future growth Basel, September 29th, 2023 — Novartis today announced that it has completed its divestment of ‘front of eye’ ophthalmology assets to Bausch + Lomb, a global eye health company, in a transaction valued up to USD 2.5 billion, consisting of 1.75 billion in upfront cash, plus potent |
Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA DrugsPer the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Huntington's diseases. |
Pliant (PLRX) Up on Success of Mid-Stage Liver Disease StudyPliant's (PLRX) phase II study on lead pipeline candidate bexotegrast, achieves its primary and secondary endpoints. Shares rise |
Ionis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5%Ionis (IONS) reports positive phase III study results, supporting the benefits of olezarsen to treat familial chylomicronemia syndrome (FCS), a rare genetic disorder. |
Novartis' (NVS) Sandoz Gets EC Nod for Tysabri's BiosimilarNovartis' (NVS) Sandoz broadens its biosimilar portfolio with Tyruko's approval, a biosimilar of the multiple sclerosis drug Tysabri in the EU. |
Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in EuropeBiosimilar Tyruko® approved for all indications of reference medicine, as first and only biosimilar to treat relapsing forms of multiple sclerosis (MS) in EuropeDecision based on evidence from extensive analytical characterization demonstrating similarity of biosimilar with reference biologic, in addition to Phase I and confirmatory Phase III studies. Sandoz is committed to accelerate access to potentially life-changing treatments, while generating savings for healthcare systems and patients aro |
Amazon Invests Up To $4B In ChatGPT Competitor, Hollywood Writers Accept Preliminary Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top StoriesBenzinga Ford Of Canada, Union Reach Collective Agreement With Wage Boosts, Pension Improvements; U.S. Negotiations Continue As Detroit-based automaker Ford Motor Co (NYSE: F) continues to reel under the impact of the United Auto Workers (UAW) union's strike in the U.S., Canada's Unifor union has ratified a new agreement with Ford of Canada. Unifor said that most of its Ford members voted in favor of a new three-year collective agreement with Ford of Canada that includes a base hourly wage incre |
Novartis (NVS) Lutathera Meets Primary Goal in Phase III StudyNovartis' (NVS) radioligand therapy Lutathera reports statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors study. |
Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer StudiesData from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints. |